Background
Growth hormone secretagogues (GHS) — compounds that stimulate GH release via the ghrelin receptor (GHSR-1a) — include peptide-based agents such as ipamorelin, GHRP-2, and GHRP-6, as well as non-peptide analogs such as MK-677. All members of this class share the pharmacological property of stimulating pulsatile GH secretion and raising IGF-1, providing an alternative to exogenous GH administration with preserved physiological pulsatility.
Svensson and colleagues at Göteborg University examined body composition and metabolic effects of the GH secretagogue class in obese males to establish whether GHS-mediated GH stimulation translates into clinically meaningful changes in body composition — directly relevant to the therapeutic utility of peptide secretagogues including ipamorelin.
Key Findings
GH Axis Stimulation:
- 24-hour mean GH concentration increased approximately 5-fold over baseline
- IGF-1 increased 52% from baseline, consistent with sustained GH axis activation
- GH pulsatility preserved: secretagogue stimulation augments endogenous pulses rather than replacing them
Body Composition (2-Month Treatment):
| Parameter | Baseline | Post-Treatment | Change |
|---|---|---|---|
| Fat-free mass (kg) | 63.4 | 65.1 | +1.7 kg* |
| Fat mass (kg) | 31.2 | 30.8 | −0.4 kg (ns) |
| Body weight (kg) | 94.6 | 95.9 | +1.3 kg (ns) |
*p < 0.05 vs. placebo
- Fat-free mass gain of 1.7 kg over 2 months without caloric restriction
- Fat mass trend downward but not statistically significant at 2-month timepoint
- BMI unchanged — the body composition shift toward lean mass is the clinically relevant finding
Metabolic Effects:
- Basal metabolic rate increased 9% from baseline — consistent with GH-mediated protein anabolism and increased lean tissue metabolic demand
- Fasting glucose unchanged; insulin sensitivity not significantly impaired within the 2-month window
- No cortisol elevation; ACTH unchanged — key differentiator from less selective GHS compounds
Mechanism Relevance to Ipamorelin
Ipamorelin is a selective GHSR-1a agonist that shares the GH secretagogue mechanism demonstrated in this study. Unlike MK-677 (non-peptide, oral), ipamorelin is administered subcutaneously and demonstrates superior selectivity — no ACTH/cortisol stimulation at therapeutic doses — but the downstream GH/IGF-1/body composition axis effects are mechanistically equivalent.
This study provides human clinical evidence for the body composition benefits expected from ipamorelin-class GH secretagogues:
- Fat-free mass accretion driven by GH-stimulated IGF-1 and protein synthesis
- Metabolic rate enhancement consistent with increased lean tissue mass
- Preserved natural GH pulsatility rather than tonic suppression of the HPG axis
Clinical Significance
- Lean mass preservation: In obese or sarcopenic patients, GHS-mediated fat-free mass gains offer an anabolic benefit without exogenous GH’s side effect profile (edema, insulin resistance)
- Metabolic rate: The 9% BMR increase provides a secondary benefit for body weight management beyond direct lipolytic effects
- Safety window: 2-month treatment showed no fasting glucose deterioration — important for obese patients at metabolic risk
- Class evidence: The shared GHSR-1a mechanism means body composition data from MK-677 trials informs expected outcomes for peptide secretagogues including ipamorelin
Limitations
- Study used MK-677 (oral, non-peptide GHS) — direct extrapolation to ipamorelin requires acknowledgment of pharmacokinetic differences (subcutaneous vs. oral; shorter vs. longer half-life)
- 2-month duration is short; long-term fat mass reduction likely requires extended treatment periods
- Male-only cohort; female body composition responses to GHS may differ due to sex-specific GH secretion patterns
- Obese population may not represent the lean, athletic, or sarcopenic populations most likely to seek ipamorelin therapy
- No control for diet or physical activity changes during the study period